Immunocheckpoint Inhibitors Articles


  • Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies.

    Urothelial carcinoma (UC) of the bladder and upper urinary tract still results an open challenge for clinical oncologists. Excluding selected patients who will particularly benefit from chemo-radiotherapy combined to endoscopic tumour removal, surgery represents the only curative approach for localized stages.

    Published June 22, 2018
  • Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma.

    Radiotherapy is living a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immunocheckpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4.

    Published October 29, 2019
  • Immunotherapy in renal cell carcinoma: latest evidence and clinical implications.

    Advances in understanding the mechanisms of tumour-induced immunosuppression have led to the development of immune-checkpoint inhibitors in cancer patients, including those with renal cell carcinoma (RCC).

    Published June 20, 2018
  • New immunotherapy in the treatment of advanced renal cancer.

    Introduction: Metastatic renal cell carcinoma (mRCC) in recent years has been one of the diseases in the oncology that has experienced the greatest development of targeted therapies.Area covered: On one hand, more and more refined acquisitions of molecular biology are allowing a better sub-classification of this tumor, identifying new and peculiar biological profiles of patients with metastatic renal cancer that will soon be destined for increasingly tailored treatments.

    Published November 25, 2019